VANDA PHARMACEUTICALS INC. Finance Lease, Principal Payments
VANDA PHARMACEUTICALS INC. (VNDA) reported Finance Lease, Principal Payments of $1.63 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:FinanceLeasePrincipalPayments · last filed 2026-08-06
- VANDA PHARMACEUTICALS INC. finance lease, principal payments for the quarter ending 2026-06-30 was $856.00K, a 101.41% increase year-over-year.
- VANDA PHARMACEUTICALS INC. finance lease, principal payments for the quarter ending 2026-03-31 was $776.00K, a 89.73% increase year-over-year.
- VANDA PHARMACEUTICALS INC. finance lease, principal payments for the quarter ending 2025-12-31 was $640.00K, a 312.90% increase year-over-year.
- VANDA PHARMACEUTICALS INC. finance lease, principal payments for the quarter ending 2025-09-30 was $517.00K.
- VANDA PHARMACEUTICALS INC. finance lease, principal payments for fiscal 2025 was $1.99M, a 1184.52% increase from fiscal 2024.
- VANDA PHARMACEUTICALS INC. finance lease, principal payments for fiscal 2024 was $155.00K.
- VANDA PHARMACEUTICALS INC. finance lease, principal payments for fiscal 2023 was $0.00.
- VANDA PHARMACEUTICALS INC. finance lease, principal payments for fiscal 2022 was $0.00.
| Period end | Finance Lease, Principal Payments 3 month | Finance Lease, Principal Payments 6 month | Finance Lease, Principal Payments 9 month | Finance Lease, Principal Payments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $856.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.63M 10-Q · filed 2026-08-06 | $2.27M derived: sum of 3 quarters · filed 2026-08-06 | $2.79M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $776.00K 10-Q · filed 2026-05-07 | $1.42M derived: sum of 2 quarters · filed 2026-05-07 | $1.93M derived: sum of 3 quarters · filed 2026-05-07 | $2.36M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $640.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $1.16M derived: sum of 2 quarters · filed 2026-02-12 | $1.58M derived: sum of 3 quarters · filed 2026-08-06 | $1.99M 10-K · filed 2026-02-12 |
| 2025-09-30 | $517.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $942.00K derived: sum of 2 quarters · filed 2026-08-06 | $1.35M 10-Q · filed 2025-10-30 | $1.51M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $425.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $834.00K 10-Q · filed 2026-08-06 | $989.00K derived: sum of 3 quarters · filed 2026-08-06 | $989.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $409.00K 10-Q · filed 2026-05-07 | $564.00K derived: sum of 2 quarters · filed 2026-05-07 | $564.00K derived: sum of 3 quarters · filed 2026-05-07 | $564.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $155.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $155.00K derived: sum of 2 quarters · filed 2026-02-12 | $155.00K derived: sum of 3 quarters · filed 2026-02-12 | $155.00K 10-K · filed 2026-02-12 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $0.00 derived: sum of 2 quarters · filed 2025-10-30 | $0.00 10-Q · filed 2025-10-30 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $0.00 10-Q · filed 2025-07-31 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-02-12 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |